429 related articles for article (PubMed ID: 29488184)
1. Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer.
Darlix A; Griguolo G; Thezenas S; Kantelhardt E; Thomssen C; Dieci MV; Miglietta F; Conte P; Braccini AL; Ferrero JM; Bailleux C; Jacot W; Guarneri V
J Neurooncol; 2018 Jun; 138(2):369-382. PubMed ID: 29488184
[TBL] [Abstract][Full Text] [Related]
2. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.
Anders CK; Deal AM; Miller CR; Khorram C; Meng H; Burrows E; Livasy C; Fritchie K; Ewend MG; Perou CM; Carey LA
Cancer; 2011 Apr; 117(8):1602-11. PubMed ID: 21472708
[TBL] [Abstract][Full Text] [Related]
3. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
Press DJ; Miller ME; Liederbach E; Yao K; Huo D
Clin Exp Metastasis; 2017 Dec; 34(8):457-465. PubMed ID: 29288366
[TBL] [Abstract][Full Text] [Related]
4. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
5. Impact of triple negative phenotype on breast cancer prognosis.
Kaplan HG; Malmgren JA
Breast J; 2008; 14(5):456-63. PubMed ID: 18657139
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.
Shen Q; Sahin AA; Hess KR; Suki D; Aldape KD; Sawaya R; Ibrahim NK
Oncologist; 2015 May; 20(5):466-73. PubMed ID: 25802405
[TBL] [Abstract][Full Text] [Related]
7. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
Leone JP; Leone J; Zwenger AO; Iturbe J; Leone BA; Vallejo CT
Eur J Cancer; 2017 Mar; 74():17-25. PubMed ID: 28335884
[TBL] [Abstract][Full Text] [Related]
9. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of breast cancer subtypes in elderly patients.
Bergen ES; Tichy C; Berghoff AS; Rudas M; Dubsky P; Bago-Horvath Z; Mader RM; Exner R; Gnant M; Zielinski CC; Steger GG; Preusser M; Bartsch R
Breast Cancer Res Treat; 2016 May; 157(1):91-9. PubMed ID: 27107570
[TBL] [Abstract][Full Text] [Related]
11. Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival.
Melisko ME; Moore DH; Sneed PK; De Franco J; Rugo HS
J Neurooncol; 2008 Jul; 88(3):359-65. PubMed ID: 18398574
[TBL] [Abstract][Full Text] [Related]
12. Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea.
Jang G; Lee SS; Ahn JH; Jung KH; Lee H; Gong G; Kim HH; Ahn SD; Son BH; Ahn SH; Kim SB
Breast Cancer Res Treat; 2011 Jul; 128(1):171-7. PubMed ID: 21519835
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
Breast; 2006 Apr; 15(2):219-25. PubMed ID: 16026983
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Brain Metastasis-Free Interval in Patients with Breast Cancer Brain Metastases.
Hulsbergen AFC; Lamba N; Claes A; Kavouridis VK; Lin NU; Smith TR; Verhoeff JJC; Broekman MLD
World Neurosurg; 2019 Aug; 128():e157-e164. PubMed ID: 31035019
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study.
Kim EK; Noh WC; Han W; Noh DY
World J Surg; 2011 Jun; 35(6):1244-53. PubMed ID: 21472372
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer subtypes and survival in patients with brain metastases.
Nam BH; Kim SY; Han HS; Kwon Y; Lee KS; Kim TH; Ro J
Breast Cancer Res; 2008; 10(1):R20. PubMed ID: 18307763
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer brain metastases - A 12 year review of treatment outcomes.
De Ieso PB; Schick U; Rosenfelder N; Mohammed K; Ross GM
Breast; 2015 Aug; 24(4):426-33. PubMed ID: 25881974
[TBL] [Abstract][Full Text] [Related]
18. Subtype switching in breast cancer brain metastases: a multicenter analysis.
Hulsbergen AFC; Claes A; Kavouridis VK; Ansaripour A; Nogarede C; Hughes ME; Smith TR; Brastianos PK; Verhoeff JJC; Lin NU; Broekman MLD
Neuro Oncol; 2020 Aug; 22(8):1173-1181. PubMed ID: 31970416
[TBL] [Abstract][Full Text] [Related]
19. Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer.
Chen M; Wu J; Liu D; Chen W; Lin C; Andriani L; Ding S; Huang O; He J; Chen X; Chen W; Li Y; Shen K; Zhu L
Clin Breast Cancer; 2022 Feb; 22(2):e147-e156. PubMed ID: 34244052
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
